Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (2299)	1/18/2001 7:40:47 PM
From: Jenna	Read Replies (2) \| Respond to of 6445

IDPH up 4 in after hours.... and DNA also! We wanted any excuse to get into DNA today in addition to the beloved IDPH, (my favorite short and long in the biotech sector bar none) and tracked this wonderful company much of the day to no avail.... Alas, the company finally reported as we expected Genentech posts rosy Q4 results tomorrow could be the chance. I thought of just getting in, but my natural caution kept me out. By Debra McGarry, CBS.MarketWatch.com Last Update: 5:46 PM ET Jan 18, 2001 NewsWatch Latest headlines Get Alerted SAN FRANCISCO (CBS.MW) -- Genentech matched Wall Street estimates Thursday as sales for the biotech firm advanced in the fourth quarter. After the market closed, the South San Francisco-based company (DNA: news, msgs) posted pro forma net income of $83.4 million, or 16 cents a share, in the quarter, nearly double the $48.1 million, or 9 cents earned in the same period last year.